NO20051108L - Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse - Google Patents
Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disseInfo
- Publication number
- NO20051108L NO20051108L NO20051108A NO20051108A NO20051108L NO 20051108 L NO20051108 L NO 20051108L NO 20051108 A NO20051108 A NO 20051108A NO 20051108 A NO20051108 A NO 20051108A NO 20051108 L NO20051108 L NO 20051108L
- Authority
- NO
- Norway
- Prior art keywords
- taxanes
- binding agent
- therapeutic use
- cytotoxic agents
- agents containing
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 5
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 239000002254 cytotoxic agent Substances 0.000 title abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 abstract 3
- 230000030833 cell death Effects 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21011202A | 2002-08-02 | 2002-08-02 | |
| US10/369,563 US7390898B2 (en) | 2002-08-02 | 2003-02-21 | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| PCT/US2003/019558 WO2004013093A2 (en) | 2002-08-02 | 2003-07-14 | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051108L true NO20051108L (no) | 2005-05-02 |
Family
ID=31498026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051108A NO20051108L (no) | 2002-08-02 | 2005-03-01 | Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7495114B2 (https=) |
| EP (1) | EP1534674A4 (https=) |
| JP (1) | JP2005539009A (https=) |
| KR (1) | KR20050032110A (https=) |
| CN (1) | CN100522955C (https=) |
| AU (1) | AU2003247587B2 (https=) |
| BR (1) | BR0313197A (https=) |
| CA (1) | CA2494074A1 (https=) |
| IL (1) | IL166624A0 (https=) |
| MX (1) | MXPA05001390A (https=) |
| NO (1) | NO20051108L (https=) |
| WO (1) | WO2004013093A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| AU2004311630A1 (en) * | 2003-12-02 | 2005-07-21 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| EP1715971A4 (en) * | 2004-01-28 | 2010-10-13 | Cytimmune Sciences Inc | FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS |
| BRPI0511754A (pt) * | 2004-06-03 | 2008-01-02 | Smithkline Beechman Cork Ltd | uso de um composto ou sais ou solvatos do mesmo |
| EP1688415A1 (en) * | 2004-12-07 | 2006-08-09 | Aventis Pharma S.A. | Cytotoxic agents comprising new C-2 modified taxanes |
| EP1669358A1 (en) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
| AU2006247471A1 (en) * | 2005-05-12 | 2006-11-23 | Tapestry Pharmaceuticals, Inc. | Molecular constructs suitable for targeted conjugates |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| ES2542152T3 (es) * | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| EP2217063B1 (en) * | 2007-11-08 | 2014-12-17 | Virginia Tech Intellectual Properties, Inc. | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| ES2702400T3 (es) * | 2010-02-03 | 2019-02-28 | Oncbiomune Inc | Composiciones que contienen un taxano o un taxoide y una proteína |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| JP6049642B2 (ja) | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| CN103648532A (zh) | 2011-06-21 | 2014-03-19 | 伊缪诺金公司 | 具有肽连接子的新型美登木素生物碱衍生物及其偶联物 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CN105121419B (zh) * | 2013-12-24 | 2016-08-03 | 于跃 | Cabazitaxel类抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法 |
| US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| ES2815353T3 (es) | 2014-09-03 | 2021-03-29 | Immunogen Inc | Derivados de benzodiazepina citotóxicos |
| WO2016090157A1 (en) | 2014-12-04 | 2016-06-09 | Celgene Corporation | Biomolecule conjugates |
| EP3769787A1 (en) | 2015-06-29 | 2021-01-27 | ImmunoGen, Inc. | Conjugates of cysteine engineered antibodies |
| SG10202106529XA (en) | 2015-07-21 | 2021-07-29 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| PT3380525T (pt) | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| TWI845890B (zh) | 2016-11-23 | 2024-06-21 | 美商伊繆諾金公司 | 苯二氮平衍生物之選擇性磺化 |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| KR20250171447A (ko) | 2017-02-28 | 2025-12-08 | 이뮤노젠 아이엔씨 | 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체 |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| TW202413360A (zh) | 2017-12-28 | 2024-04-01 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| AU2020241896A1 (en) | 2019-03-20 | 2021-09-23 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| JP7682797B2 (ja) | 2019-03-20 | 2025-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン６二重特異性抗体 |
| EP3947395A1 (en) | 2019-03-29 | 2022-02-09 | ImmunoGen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| JP7561141B2 (ja) | 2019-04-26 | 2024-10-03 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| MX2022010457A (es) | 2020-02-25 | 2022-11-16 | Mediboston Ltd | Derivados de camptotecina y conjugados de esta. |
| EP4178624A2 (en) | 2020-07-07 | 2023-05-17 | Bionecure Therapeutics, Inc. | Maytansinoids as adc payloads and their use for the treatment of cancer |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| US12521444B2 (en) | 2021-02-25 | 2026-01-13 | Fortvita Biologics Limited | Anti-HER2 antibody-drug conjugates and uses thereof |
| JP2025524986A (ja) | 2022-07-27 | 2025-08-01 | メディボストン リミテッド | オーリスタチン誘導体およびそのコンジュゲート |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5399726A (en) | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
| US5728725A (en) | 1991-09-23 | 1998-03-17 | Florida State University | C2 taxane derivaties and pharmaceutical compositions containing them |
| US6028205A (en) | 1991-09-23 | 2000-02-22 | Florida State University | C2 tricyclic taxanes |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5356928A (en) * | 1992-11-06 | 1994-10-18 | Hauser Chemical Research, Inc. | Cytotoxic agents |
| US5646176A (en) * | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| IL108443A0 (en) * | 1993-01-29 | 1994-04-12 | Univ Florida State | C7 taxane derivatives and pharmaceutical compositions containing them |
| US6339164B1 (en) | 1993-01-29 | 2002-01-15 | Florida State University | C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them |
| US5703247A (en) * | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
| US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2129288C (en) * | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| WO1996011683A1 (en) * | 1994-10-14 | 1996-04-25 | Hauser Chemical Research, Inc. | New cytotoxic agents |
| WO1996023779A1 (en) * | 1995-02-02 | 1996-08-08 | Daiichi Pharmaceutical Co., Ltd. | Ether derivative |
| CN1211919A (zh) * | 1995-09-13 | 1999-03-24 | 佛罗里达州立大学 | 放射增敏性紫杉烷及其药物制剂 |
| WO1997044026A1 (en) | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
| JP2001505194A (ja) | 1996-11-05 | 2001-04-17 | ブリストル―マイヤーズ・スクイブ・カンパニー | 分枝ペプチド・リンカー |
| US5811452A (en) | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
| IL132941A0 (en) | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| WO1999018113A1 (fr) * | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| US6545125B1 (en) | 1997-11-18 | 2003-04-08 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
| US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| AU768027B2 (en) * | 1999-02-24 | 2003-11-27 | Uab Research Foundation, The | Taxane derivatives for targeted therapy of cancer |
| ES2276708T3 (es) * | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| US6175023B1 (en) | 2000-01-31 | 2001-01-16 | Jian Liu | Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III |
| IL145637A0 (en) * | 2000-02-02 | 2002-06-30 | Univ Florida State Res Found | C7 carbonate substituted taxanes as antitumor agents |
| AU778991B2 (en) * | 2000-02-02 | 2004-12-23 | Florida State University Research Foundation, Inc. | C7 carbamoyloxy substituted taxanes as antitumor agents |
| AU776765B2 (en) * | 2000-02-02 | 2004-09-23 | Florida State University Research Foundation, Inc. | C7 heterosubstituted acetate taxanes as antitumor agents |
| KR20010111580A (ko) * | 2000-02-02 | 2001-12-19 | 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 | 개선된 용해도를 갖는 탁산 제형물 |
| CZ20013523A3 (cs) * | 2000-02-02 | 2002-03-13 | Florida State University Research Foundation, Inc. | Taxany s C10 heterosubstituovaným acetátem jako protinádorové látky |
| US6596757B1 (en) * | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
-
2003
- 2003-07-14 CN CNB038232480A patent/CN100522955C/zh not_active Expired - Fee Related
- 2003-07-14 CA CA002494074A patent/CA2494074A1/en not_active Abandoned
- 2003-07-14 WO PCT/US2003/019558 patent/WO2004013093A2/en not_active Ceased
- 2003-07-14 KR KR1020057001946A patent/KR20050032110A/ko not_active Ceased
- 2003-07-14 JP JP2004526000A patent/JP2005539009A/ja active Pending
- 2003-07-14 EP EP03766820A patent/EP1534674A4/en not_active Withdrawn
- 2003-07-14 MX MXPA05001390A patent/MXPA05001390A/es active IP Right Grant
- 2003-07-14 AU AU2003247587A patent/AU2003247587B2/en not_active Ceased
- 2003-07-14 BR BR0313197-1A patent/BR0313197A/pt not_active IP Right Cessation
-
2004
- 2004-08-26 US US10/926,192 patent/US7495114B2/en not_active Expired - Fee Related
- 2004-10-14 US US10/963,711 patent/US7414073B2/en not_active Expired - Fee Related
-
2005
- 2005-02-01 IL IL16662405A patent/IL166624A0/xx unknown
- 2005-03-01 NO NO20051108A patent/NO20051108L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050085513A1 (en) | 2005-04-21 |
| IL166624A0 (en) | 2006-01-15 |
| US20050026997A1 (en) | 2005-02-03 |
| CA2494074A1 (en) | 2004-02-12 |
| EP1534674A2 (en) | 2005-06-01 |
| EP1534674A4 (en) | 2007-11-28 |
| JP2005539009A (ja) | 2005-12-22 |
| AU2003247587A1 (en) | 2004-02-23 |
| US7414073B2 (en) | 2008-08-19 |
| CN1684948A (zh) | 2005-10-19 |
| MXPA05001390A (es) | 2005-07-29 |
| WO2004013093A3 (en) | 2004-07-01 |
| CN100522955C (zh) | 2009-08-05 |
| WO2004013093A2 (en) | 2004-02-12 |
| US7495114B2 (en) | 2009-02-24 |
| KR20050032110A (ko) | 2005-04-06 |
| BR0313197A (pt) | 2005-08-09 |
| AU2003247587B2 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051108L (no) | Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse | |
| DK1242401T3 (da) | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf | |
| DK1242438T3 (da) | Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse | |
| AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
| KR20030086596A (ko) | α,β불포화아릴 술폰을 이용한 이온화 방사선독성으로부터의 세포 및 조직 보호방법 | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| CO4290417A1 (es) | Nuevas benzoilguanidinas como medicamentos y su preparacion . | |
| SE0202463D0 (sv) | Novel compounds | |
| DK0923570T3 (da) | Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| UA86957C2 (ru) | Производные азепиноиндола в качестве фармацевтического средства | |
| ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| NO20070576L (no) | Nye hydantionderivater for behandling av obstruktive luftveissykdommer. | |
| GEP20032869B (en) | Alpha -Ketoamide Inhibitors of 20S Proteasome, Pharmaceutical Preparations Containing the Same and Methods for Treatment | |
| IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| NO952132D0 (no) | Farmakologiske aktive pyridin-derivater og deres fremstilling | |
| WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
| NO20072915L (no) | Farmasoytisk preparat som inneholder belagte magnetiske partikler og fremgangsmate for fremstilling av disse, og diagnoseterapisystem | |
| IS7965A (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| ATE302203T1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| SE0302756D0 (sv) | Novel Compounds | |
| DK1419240T3 (da) | Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutika |